Compare abrdn Income Credit Strategies Fund (ACP) vs ADMA Biologics Inc (ADMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs ADMA Biologics Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $637.39M), while ADMA Biologics Inc trades at $9.81 (market cap $2.18B). The key difference: ADMA Biologics Inc is far larger — about 3.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.31% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ACP | ADMA | |
|---|---|---|
Market Cap | $637.39M | $2.18B |
Sector | Financials | Health |
52-Week High | $5.98 | $20.38 |
52-Week Low | $5.01 | $7.60 |
Dividend Yield | 18.31% | — |
Enterprise Value | — | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.08, up 0.4% today, with a bearish technical signal from moving averages and a neutral stance from oscillators. The stock shows a low P/E of 7.7 and P/B of 0.9, indicating potential undervaluation, while net income margin remains high at 95.31%. Recent news highlights dividend declarations but also concerns over distribution sustainability from Seeking Alpha (2026-05-29).
The outlook is mixed: attractive valuation and dividends offer income appeal, but technical weakness and high distribution reliance pose risks. Investors should weigh the fund's high yield against credit spread tightness and leverage exposure noted in analyst reports.
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →
